Subtype
Diffuse Midline Glioma
CI-CAN-00005114Explore in graph →
61 active trials1 approved drugs15 evidence items
- NCIt
- C182151
Loading cancer entity…
Subtype
CI-CAN-00005114Explore in graph →
Clinical trials
129 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (23)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03620032 | Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses(DIPG) | unknown | Phase 2 | 54 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT02233049 | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication(BIOMEDE) | unknown | Phase 2 | 250 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 |
| Jul 23, 2018 |
| clinicaltrials |
| NCT01952769 | Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma | unknown | Phase 1 / Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Sep 13, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Dec 6, 2023source: clinicaltrials